91. |
92. |
93. Dynamic contrast-enhanced MRI in malignant pleural mesothelioma : prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapyMartina Vivoda Tomšič, Peter Korošec, Viljem Kovač, Sotirios Bisdas, Katarina Šurlan Popović, 2022, original scientific article Abstract: The malignant pleural mesothelioma (MPM) response rate to chemotherapy is low. The identification of imaging biomarkers that could help guide the most effective therapy approach for individual patients is highly desirable. Our aim was to investigate the dynamic contrast-enhanced (DCE) MR parameters as predictors for progression-free (PFS) and overall survival (OS) in patients with MPM treated with cisplatin-based chemotherapy. Methods: Thirty-two consecutive patients with MPM were enrolled in this prospective study. Pretreatment and intratreatment DCE-MRI were scheduled in each patient. The DCE parameters were analyzed using the extended Tofts (ET) and the adiabatic approximation tissue homogeneity (AATH) model. Comparison analysis, logistic regression and ROC analysis were used to identify the predictors for the patient's outcome. Results: Patients with higher pretreatment ET and AATH-calculated Ktrans and ve values had longer OS (P≤.006). Patients with a more prominent reduction in ET-calculated Ktrans and kep values during the early phase of chemotherapy had longer PFS (P =.008). No parameter was identified to predict PFS. Pre-treatment ET-calculated Ktrans was found to be an independent predictive marker for longer OS (P=.02) demonstrating the most favourable discrimination performance compared to other DCE parameters with an estimated sensitivity of 89% and specificity of 78% (AUC 0.9, 95% CI 0.74-0.98, cut off > 0.08 min-1). Conclusions: In the present study, higher pre-treatment ET-calculated Ktrans values were associated with longer OS. The results suggest that DCE-MRI might provide additional information for identifying MPM patients that may respond to chemotherapy.
Keywords: cisplatin, magnetic resonance imaging, mesothelioma
Published in DiRROS: 06.04.2022; Views: 1147; Downloads: 497
 Full text (1,55 MB)
This document has many files! More... |
94. Aktivacija citosolnih senzorjev DNA po obsevanjuTanja Jesenko, Maša Omerzel, Boštjan Markelc, Gregor Serša, Katarina Žnidar, Loree C. Heller, Maja Čemažar, 2021, published scientific conference contribution Keywords: citosolni senzorji, eksperimentalna onkologija, obsevanje
Published in DiRROS: 01.04.2022; Views: 602; Downloads: 195
Full text (301,58 KB) |
95. |
96. Priporočila za obravnavo bolnikov z melanomomMarko Hočevar, Primož Strojan, Janja Ocvirk, Barbara Perić, Olga Blatnik, Boštjan Luzar, Jože Pižem, Marko Boc, Tanja Mesti, Marija Ignjatović, Nežka Hribernik, Katarina Barbara Karner, Tomi Bremec, Tanja Planinšek Ručigaj, 2020, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: onkologija, melanomi, maligni melanomi, UV žarki, sončenje, sončne opekline, zaščitne kreme
Published in DiRROS: 18.03.2022; Views: 689; Downloads: 237
Full text (739,88 KB) |
97. Kožni melanom : klinična potBarbara Perić, Martina Reberšek, Tanja Mesti, Marko Boc, Katarina Barbara Karner, Primož Strojan, Janja Ocvirk, Marko Hočevar, 2020, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: melanom, rak kože, bolniki, zdravljenje
Published in DiRROS: 16.03.2022; Views: 717; Downloads: 327
Full text (663,59 KB)
This document has many files! More... |
98. Karcinom Merklovih celic : klinična potBarbara Perić, Primož Strojan, Janja Ocvirk, Marko Hočevar, Marko Boc, Katarina Barbara Karner, Martina Reberšek, 2020, other monographs and other completed works Keywords: melanom, rak kože, bolniki, zdravljenje
Published in DiRROS: 14.03.2022; Views: 662; Downloads: 324
Full text (368,33 KB)
This document has many files! More... |
99. Utility of telomerase gene mutation testing in patients with idiopathic pulmonary fibrosis in routine practiceJulij Šelb, Katarina Osolnik, Izidor Kern, Peter Korošec, Matija Rijavec, 2022, original scientific article Abstract: Recent studies have suggested that causative variants in telomerase complex genes (TCGs) are present in around 10% of individuals with idiopathic pulmonary fibrosis (IPF) regardless of family history of the disease. However, the studies used a case-control rare variant enrichment study design which is not directly translatable to routine practice. To validate the prevalence results and to establish the individual level, routine clinical practice, and utility of those results we performed next generation sequencing of TCGs on a cohort of well-characterized consecutive individuals with IPF (diagnosis established according to ATS/ERS/JRS/ALAT guidelines). Of 27 IPF patients, three had a family history of idiopathic interstitial pneumonia (familial IPF) and 24 did not (sporadic IPF). Pathogenic/likely-pathogenic variants (according to American College of Medical Genetics criteria) in TCG were found in three individuals (11.1%) of the whole cohort; specifically, they were present in 2 out of 24 (8.3%) of the sporadic and in 1 out of 3 (33.3%) of the patients with familial IPF. Our results, which were established on an individual-patient level study design and in routine clinical practice (as opposed to the case-control study design), are roughly in line with the around 10% prevalence of causative TCG variants in patients with IPF.
Keywords: telomerase, idiopathic pulmonary fibrosis, genetic variation, telomerase complex
Published in DiRROS: 07.02.2022; Views: 804; Downloads: 370
Full text (236,11 KB) |
100. |
